{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T02:56:44Z","timestamp":1793329004459,"version":"4.5.0"},"reference-count":14,"publisher":"Society of Nuclear Medicine","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Nucl Med"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.2967\/jnumed.123.266842","type":"journal-article","created":{"date-parts":[[2024,3,14]],"date-time":"2024-03-14T18:00:51Z","timestamp":1710439251000},"page":"735-739","source":"Crossref","is-referenced-by-count":16,"title":["Real-World Experience with<sup>177<\/sup>Lu-PSMA-617 Radioligand Therapy After Food and Drug Administration Approval"],"prefix":"10.2967","volume":"65","author":[{"given":"Abuzar","family":"Moradi Tuchayi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Surekha","family":"Yadav","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarasa T.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachelle K.","family":"Saelee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Morley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roxanna","family":"Juarez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Courtney","family":"Lawhn-Heath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingbing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"de Kouchkovsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas A.","family":"Hope","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1602","published-online":{"date-parts":[[2024,3,14]]},"reference":[{"key":"2024050106051098000_65.5.735.1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21332"},{"key":"2024050106051098000_65.5.735.2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1701695"},{"key":"2024050106051098000_65.5.735.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2018.03.028"},{"key":"2024050106051098000_65.5.735.4","doi-asserted-by":"publisher","DOI":"10.1016\/1078-1439(95)00002-Y"},{"key":"2024050106051098000_65.5.735.5","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s11912-021-01042-w","article-title":"Prostate-specific membrane antigen (PSMA)-targeted radionuclide therapies for prostate cancer","volume":"23","author":"Sun","year":"2021","journal-title":"Curr Oncol Rep."},{"key":"2024050106051098000_65.5.735.6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2107322"},{"key":"2024050106051098000_65.5.735.7","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00237-3"},{"key":"2024050106051098000_65.5.735.8","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.121.263638"},{"issue":"5","key":"2024050106051098000_65.5.735.9","first-page":"14N","article-title":"Updates to appropriate use criteria for PSMA PET","volume":"63","author":"Hope","year":"2022","journal-title":"J Nucl Med ."},{"key":"2024050106051098000_65.5.735.10","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/S1470-2045(21)00274-6","article-title":"Nomograms to predict outcomes after 177Lu-PSMA therapy in men with metastatic castration-resistant prostate cancer: an international, multicentre, retrospective study","volume":"22","author":"Gafita","year":"2021","journal-title":"Lancet Oncol."},{"key":"2024050106051098000_65.5.735.11","doi-asserted-by":"crossref","first-page":"7812","DOI":"10.7150\/thno.47251","article-title":"Analysis of PSMA expression and outcome in patients with advanced prostate cancer receiving 177Lu-PSMA-617 radioligand therapy","volume":"10","author":"Seifert","year":"2020","journal-title":"Theranostics."},{"key":"2024050106051098000_65.5.735.12","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.118.219352"},{"key":"2024050106051098000_65.5.735.13","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.122.265346"},{"key":"2024050106051098000_65.5.735.14","doi-asserted-by":"crossref","unstructured":"Emmett L John N Pathmanandavel S . Patient outcomes following a response biomarker-guided approach to treatment using 177Lu-PSMA-I&T in men with metastatic castrate-resistant prostate cancer (Re-SPECT). Ther Adv Med Oncol. 2023;15:17588359231156392.","DOI":"10.1177\/17588359231156392"}],"container-title":["Journal of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.2967\/jnumed.123.266842","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T15:00:54Z","timestamp":1714575654000},"score":1,"resource":{"primary":{"URL":"http:\/\/jnm.snmjournals.org\/lookup\/doi\/10.2967\/jnumed.123.266842"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,14]]},"references-count":14,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2024,5,1]]},"published-print":{"date-parts":[[2024,5]]}},"alternative-id":["10.2967\/jnumed.123.266842"],"URL":"https:\/\/doi.org\/10.2967\/jnumed.123.266842","relation":{},"ISSN":["0161-5505","2159-662X"],"issn-type":[{"value":"0161-5505","type":"print"},{"value":"2159-662X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,14]]}}}